The somatically generated portion of the T cell receptor CDR3α contributes to the MHC allele specificity of the T cell receptor

  1. Philippa Marrack  Is a corresponding author
  2. Sai Harsha Krovi
  3. Daniel Silberman
  4. Janice White
  5. Eleanor Kushnir
  6. Maki Nakayama
  7. James Crooks
  8. Thomas Danhorn
  9. Sonia Leach
  10. Randy Anselment
  11. James Scott-Browne
  12. Laurent Gapin
  13. John Kappler
  1. Howard Hughes Medical Institute, National Jewish Health, United States
  2. University of Colorado School of Medicine, United States
  3. National Jewish Health, United States
  4. La Jolla Institute for Allergy and Immunology, United States

Abstract

Mature T cells bearing αβ T cell receptors react with foreign antigens bound to alleles of major histocompatibility complex proteins (MHC) that they were exposed to during their development in the thymus, a phenomenon known as positive selection. The structural basis for positive selection has long been debated. Here, using mice expressing one of two different T cell receptor β chains and various MHC alleles, we show that positive selection-induced MHC bias of T cell receptors is affected both by the germline encoded elements of the T cell receptor α and β chain and, surprisingly, dramatically affected by the non germ line encoded portions of CDR3 of the T cell receptor α chain. Thus, in addition to determining specificity for antigen, the non germline encoded elements of T cell receptors may help the proteins cope with the extremely polymorphic nature of major histocompatibility complex products within the species.

Data availability

The following data sets were generated

Article and author information

Author details

  1. Philippa Marrack

    Howard Hughes Medical Institute, National Jewish Health, Denver, United States
    For correspondence
    MarrackP@NJHealth.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1883-3687
  2. Sai Harsha Krovi

    Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Daniel Silberman

    Department of Biomedical Research, National Jewish Health, Denver, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Janice White

    Department of Biomedical Research, National Jewish Health, Denver, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Eleanor Kushnir

    Department of Biomedical Research, National Jewish Health, Denver, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Maki Nakayama

    Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. James Crooks

    Division of Biostatistics and Bioinformatics, National Jewish Health, Denver, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Thomas Danhorn

    Division of Biostatistics and Bioinformatics, National Jewish Health, Denver, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3861-8602
  9. Sonia Leach

    Department of Biomedical Research, National Jewish Health, Denver, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Randy Anselment

    Division of Biostatistics and Bioinformatics, National Jewish Health, Denver, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. James Scott-Browne

    La Jolla Institute for Allergy and Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Laurent Gapin

    Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. John Kappler

    Howard Hughes Medical Institute, National Jewish Health, Denver, United States
    Competing interests
    The authors declare that no competing interests exist.

Funding

National Institutes of Health (AI 18785)

  • Philippa Marrack

National Institutes of Health (AI 092108)

  • Laurent Gapin

National Institutes of Health (AI 103736)

  • Laurent Gapin

Howard Hughes Medical Institute (NA)

  • John Kappler

National Institutes of Health (DK099317)

  • Maki Nakayama

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (AC-2517) of National Jewish Health. The protocol was approved by the Institutional Animal Care and Use Committee of National Jewish Health. Every effort was made to minimize suffering.

Copyright

© 2017, Marrack et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,940
    views
  • 284
    downloads
  • 23
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Philippa Marrack
  2. Sai Harsha Krovi
  3. Daniel Silberman
  4. Janice White
  5. Eleanor Kushnir
  6. Maki Nakayama
  7. James Crooks
  8. Thomas Danhorn
  9. Sonia Leach
  10. Randy Anselment
  11. James Scott-Browne
  12. Laurent Gapin
  13. John Kappler
(2017)
The somatically generated portion of the T cell receptor CDR3α contributes to the MHC allele specificity of the T cell receptor
eLife 6:e30918.
https://doi.org/10.7554/eLife.30918

Share this article

https://doi.org/10.7554/eLife.30918

Further reading

    1. Immunology and Inflammation
    Aryeh Solomon, Noa Bossel Ben-Moshe ... Roi Avraham
    Research Article

    Trained immunity (TI) is the process wherein innate immune cells gain functional memory upon exposure to specific ligands or pathogens, leading to augmented inflammatory responses and pathogen clearance upon secondary exposure. While the differentiation of hematopoietic stem cells (HSCs) and reprogramming of bone marrow (BM) progenitors are well-established mechanisms underpinning durable TI protection, remodeling of the cellular architecture within the tissue during TI remains underexplored. Here, we study the effects of peritoneal Bacillus Calmette–Guérin (BCG) administration to find TI-mediated protection in the spleen against a subsequent heterologous infection by the Gram-negative pathogen Salmonella Typhimurium (S.Tm). Utilizing single cell RNA-sequencing and flow cytometry, we discerned STAT1-regulated genes in TI-associated resident and recruited splenic myeloid populations. The temporal dynamics of TI were further elucidated, revealing both early and delayed myeloid subsets with time-dependent, cell-type-specific STAT1 signatures. Using lineage tracing, we find that tissue-resident red pulp macrophages (RPM), initially depleted by BCG exposure, are restored from both tissue-trained, self-renewing macrophages and from bone marrow-derived progenitors, fostering long lasting local defense. Early inhibition of STAT1 activation, using specific JAK-STAT inhibitors, reduces both RPM loss and recruitment of trained monocytes. Our study suggests a temporal window soon after BCG vaccination, in which STAT1-dependent activation of long-lived resident cells in the tissue mediates localized protection.

    1. Immunology and Inflammation
    Yalan Jiang, Pingping He ... Xiaoou Shan
    Research Article

    Type 1 diabetes mellitus (T1DM), known as insulin-dependent diabetes mellitus, is characterized by persistent hyperglycemia resulting from damage to the pancreatic β cells and an absolute deficiency of insulin, leading to multi-organ involvement and a poor prognosis. The progression of T1DM is significantly influenced by oxidative stress and apoptosis. The natural compound eugenol (EUG) possesses anti-inflammatory, anti-oxidant, and anti-apoptotic properties. However, the potential effects of EUG on T1DM had not been investigated. In this study, we established the streptozotocin (STZ)-induced T1DM mouse model in vivo and STZ-induced pancreatic β cell MIN6 cell model in vitro to investigate the protective effects of EUG on T1DM, and tried to elucidate its potential mechanism. Our findings demonstrated that the intervention of EUG could effectively induce the activation of nuclear factor E2-related factor 2 (NRF2), leading to an up-regulation in the expressions of downstream proteins NQO1 and HMOX1, which are regulated by NRF2. Moreover, this intervention exhibited a significant amelioration in pancreatic β cell damage associated with T1DM, accompanied by an elevation in insulin secretion and a reduction in the expression levels of apoptosis and oxidative stress-related markers. Furthermore, ML385, an NRF2 inhibitor, reversed these effects of EUG. The present study suggested that EUG exerted protective effects on pancreatic β cells in T1DM by attenuating apoptosis and oxidative stress through the activation of the NRF2 signaling pathway. Consequently, EUG holds great promise as a potential therapeutic candidate for T1DM.